Valion Bio

VBIO · NASDAQ

$1.19+$0.03 (+2.59%)TodayMarket closed ·
Prev close $1.16

About VBIO

Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company is headquartered in San Antonio, Texas and currently employs 52 full-time employees. The company went IPO on 2021-11-11. The firm offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. The company offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services.

Employees
52
Headquarters
San Antonio, Texas
Listed
Nov 11, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies

VBIO key statistics

Market cap
2.28M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.17M
Volume
45.48K
Open price
$1.12
High today
$1.26
Low today
$1.11
52 Week high
$32.50
52 Week low
$1.05

Valion Bio (VBIO) at a glance

As of Oct 20, 2026, Valion Bio (VBIO) shares are priced at $1.19, giving the company a market cap of 2.28M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.11 and $1.26. The current price is 7.2% above the day's low and 5.5% below its high.

Volume so far is 45.48K shares, below the average of 4.17M shares a day.

Over the past year Valion Bio has ranged from $1.05 to $32.50, and now sits 0% of the way up that range.

Valion Bio met or beat analyst EPS estimates in 6 of the last 7 quarters. In Q2 FY24 it reported -$0.32 per share against an estimate of -$6.12.

VBIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 7 quarters, by 39.2% on average.

  1. Q2 FY22: reported -$544.00 per share against an estimate of -$416.16
  2. Q3 FY22: reported -$459.00 per share against an estimate of -$554.88
  3. Q4 FY22: reported -$289.00 per share against an estimate of -$398.82
  4. Q1 FY23: reported -$187.00 per share against an estimate of -$190.74
  5. Q2 FY23: reported -$119.00 per share against an estimate of -$138.72
  6. Q3 FY23: reported -$25.16 per share against an estimate of -$121.38
  7. Q2 FY24: reported -$0.32 per share against an estimate of -$6.12

VBIO news

  • Press releaseGlobe Newswire

    3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

  • Press releasePRNewswire

    World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Similar companies

Companies in the same industry as Valion Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.